Ken Mills

President & Chief Executive Officer
Regenxbio Inc.

Ken Mills is the founding president and chief executive officer of REGENXBIO, a biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Under Mills’ leadership, REGENXBIO completed its initial public offering in 2015.

Prior to REGENXBIO, Mills was a partner at FoxKiser, a biomedical research and development, law and public policy firm. Previously, Mills was the chief financial officer and vice president of business development at Meso Scale Diagnostics, a privately held life sciences company. There, Mills served as a member of the founding management team, and worked to establish the company's operations and ongoing business strategy. In this position, Mills supervised all company activities, including direct management of corporate and business development, strategic planning, finance and accounting activities. Prior to Meso Scale Diagnostics, Mills was director of business development for IGEN International, a medical diagnostics company.